Amy M Berkman1, Karly M Murphy2, Elizabeth J Siembida3, Nancy Lau4, Yimin Geng5, Susan K Parsons6, John M Salsman2, Michael E Roth7. 1. Department of Pediatrics, Duke University School of Medicine, Durham, NC, USA. 2. Department of Social Sciences and Health Policy, Wake Forest School of Medicine, Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, NC, USA. 3. Center for Health Innovation and Outcomes Research, Northwell Health, Manhasset, NY, USA. 4. Center for Clinical and Translational Research, Palliative Care and Resilience Research Center, Seattle Children's Research Institute, Seattle, WA, USA; Department of Psychiatry and Behavioral Sciences, University of Washington School of Medicine, Seattle, WA, USA. 5. Research Medical Library, University of Texas MD Anderson Cancer Center, Houston, TX, USA. 6. Institute for Clinical Research and Health Policy Studies and the Division of Hematology/Oncology, Tufts Medical Center, Tufts University School of Medicine, Boston, MA, USA. 7. Division of Pediatrics, University of Texas MD Anderson Cancer Center, Houston, TX, USA. Electronic address: mroth1@mdanderson.org.
Abstract
OBJECTIVES: There is a paucity of research on the impact of cancer treatment on the health-related quality of life (HRQOL) of adolescent and young adult (AYA) patients with cancer. Patient-reported outcomes (PROs) are self-report measures used to assess HRQOL and symptom burden. The extent to which PROs have been included in trials that include common AYA cancer types has not been previously assessed. METHODS: Therapeutic phase 3 trials among common AYA cancer types (Hodgkin lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, sarcomas, and germ cell tumors) initiated between 2007 and 2020 were identified on ClinicalTrials.gov. The proportions and characteristics of trials including a PRO endpoint were assessed. For comparison with an older population, the proportion of breast and colorectal therapeutic phase 3 trials including PRO endpoints were assessed. RESULTS: Eighty-seven studies met the inclusion criteria. Overall, 20.7% of therapeutic phase 3 AYA trials included a PRO endpoint, and only one trial published PRO data. Germ cell tumors (42.9%) and non-Hodgkin lymphoma (40%) trials had the highest proportions of PRO inclusion. The European Organization for Research and Treatment of Cancer generic, cancer-specific quality of life questionnaire was the most commonly used PRO measure; nevertheless, the measures used varied within and between cancer types. The proportion of trials including a PRO endpoint did not change significantly between 2007 to 2013 and 2014 to 2020 (18.6% vs 22.7%, P=.79). CONCLUSIONS: Few therapeutic phase 3 AYA cancer trials include PRO endpoints, fewer publish PRO data, and there is no homogeneity in the measures administered. Therapeutic trials represent an underused opportunity to capture PRO data in the AYA population with the goal of improving HRQOL outcomes.
OBJECTIVES: There is a paucity of research on the impact of cancer treatment on the health-related quality of life (HRQOL) of adolescent and young adult (AYA) patients with cancer. Patient-reported outcomes (PROs) are self-report measures used to assess HRQOL and symptom burden. The extent to which PROs have been included in trials that include common AYA cancer types has not been previously assessed. METHODS: Therapeutic phase 3 trials among common AYA cancer types (Hodgkin lymphoma, non-Hodgkin lymphoma, acute lymphoblastic leukemia, sarcomas, and germ cell tumors) initiated between 2007 and 2020 were identified on ClinicalTrials.gov. The proportions and characteristics of trials including a PRO endpoint were assessed. For comparison with an older population, the proportion of breast and colorectal therapeutic phase 3 trials including PRO endpoints were assessed. RESULTS: Eighty-seven studies met the inclusion criteria. Overall, 20.7% of therapeutic phase 3 AYA trials included a PRO endpoint, and only one trial published PRO data. Germ cell tumors (42.9%) and non-Hodgkin lymphoma (40%) trials had the highest proportions of PRO inclusion. The European Organization for Research and Treatment of Cancer generic, cancer-specific quality of life questionnaire was the most commonly used PRO measure; nevertheless, the measures used varied within and between cancer types. The proportion of trials including a PRO endpoint did not change significantly between 2007 to 2013 and 2014 to 2020 (18.6% vs 22.7%, P=.79). CONCLUSIONS: Few therapeutic phase 3 AYA cancer trials include PRO endpoints, fewer publish PRO data, and there is no homogeneity in the measures administered. Therapeutic trials represent an underused opportunity to capture PRO data in the AYA population with the goal of improving HRQOL outcomes.
Authors: Chandylen L Nightingale; Gwendolyn P Quinn; Elizabeth A Shenkman; Barbara A Curbow; Bradley J Zebrack; Kevin R Krull; I-Chan Huang Journal: J Adolesc Young Adult Oncol Date: 2011-09 Impact factor: 2.223
Authors: Corneel Coens; Madeline Pe; Amylou C Dueck; Jeff Sloan; Ethan Basch; Melanie Calvert; Alicyn Campbell; Charles Cleeland; Kim Cocks; Laurence Collette; Nancy Devlin; Lien Dorme; Hans-Henning Flechtner; Carolyn Gotay; Ingolf Griebsch; Mogens Groenvold; Madeleine King; Paul G Kluetz; Michael Koller; Daniel C Malone; Francesca Martinelli; Sandra A Mitchell; Jammbe Z Musoro; Daniel O'Connor; Kathy Oliver; Elisabeth Piault-Louis; Martine Piccart; Chantal Quinten; Jaap C Reijneveld; Christoph Schürmann; Ashley Wilder Smith; Katherine M Soltys; Martin J B Taphoorn; Galina Velikova; Andrew Bottomley Journal: Lancet Oncol Date: 2020-02 Impact factor: 41.316
Authors: Maria Olsson; Gunnar Steineck; Karin Enskär; Ulrica Wilderäng; Marianne Jarfelt Journal: J Cancer Surviv Date: 2018-03-05 Impact factor: 4.442
Authors: Stephen A Sands; Brian T Harel; Mirko Savone; Kara Kelly; Veena Vijayanathan; Jennifer Greene Welch; Lynda Vrooman; Lewis B Silverman; Peter D Cole Journal: Support Care Cancer Date: 2016-10-10 Impact factor: 3.603
Authors: Deborah Watkins Bruner; Charlene J Bryan; Neil Aaronson; C Craig Blackmore; Michael Brundage; David Cella; Patricia A Ganz; Carolyn Gotay; Pamela S Hinds; Alice B Kornblith; Benjamin Movsas; Jeff Sloan; Lari Wenzel; Giles Whalen Journal: J Clin Oncol Date: 2007-11-10 Impact factor: 44.544
Authors: Katie Young; Ksenya Shliakhtsitsava; Loki Natarajan; Emily Myers; Andrew C Dietz; Jessica R Gorman; María Elena Martínez; Brian W Whitcomb; H Irene Su Journal: Cancer Date: 2018-11-29 Impact factor: 6.860
Authors: Joseph R Henderson; Elizabeth Kiernan; Jennifer L McNeer; Angie Mae Rodday; Katherine Spencer; Tara O Henderson; Susan K Parsons Journal: J Adolesc Young Adult Oncol Date: 2017-11-30 Impact factor: 2.223
Authors: Tanya Lazor; Leonie Tigelaar; Jason D Pole; Claire De Souza; Deborah Tomlinson; Lillian Sung Journal: Support Care Cancer Date: 2017-06-03 Impact factor: 3.603
Authors: Helen M Parsons; Dolly C Penn; Qian Li; Rosemary D Cress; Brad H Pollock; Marcio H Malogolowkin; Ted Wun; Theresa H M Keegan Journal: Pediatr Blood Cancer Date: 2018-09-06 Impact factor: 3.838
Authors: Kelsey L Corrigan; Shuangshuang Fu; Ying-Shiuan Chen; Kelsey Kaiser; Michael Roth; Susan K Peterson; Ya-Chen T Shih; Reshma Jagsi; Sharon H Giordano; Robert J Volk; K Robin Yabroff; Mathew P Banegas; Chiara Acquati; Rena M Conti; Hilary Y Ma; Kimberly Ku; Y Nancy You; Grace L Smith Journal: Cancer Date: 2022-04-13 Impact factor: 6.921